(Q35023701)

5 August 2017

title

Addressing phenoconversion: the Achilles' heel of personalized medicine (English)

1 reference

5 August 2017

main subject

personalized medicine

1 reference

Rashmi R Shah

1

1 reference

5 August 2017

Robert L Smith

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 February 2015

1 reference

British Journal of Clinical Pharmacology

5 August 2017

published in

1 reference

5 August 2017

volume

79

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

222-240

1 reference

Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The endogenous substrates of brain CYP2D.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

A pharmacogenetic versus a clinical algorithm for warfarin dosing

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Potential role of CYP2D6 in the central nervous system

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Applications of CYP450 testing in the clinical setting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Tamoxifen and CYP2D6: a contradiction of data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The prevalence of co-administration of clopidogrel and proton pump inhibitors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Herb-drug pharmacokinetic interactions reviewed.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Clopidogrel with or without omeprazole in coronary artery disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Cholesteryl ester transfer protein and its inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

KCNH2 pharmacogenomics summary

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Variability in drug metabolizing enzyme activity in HIV-infected patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Glucose control by the kidney: an emerging target in diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Estimation of the warfarin dose with clinical and pharmacogenetic data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The largest prospective warfarin-treated cohort supports genetic forecasting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Differential genotype dependent inhibition of CYP2C9 in humans

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Herb-drug interactions: a literature review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Inhibition of CYP2D6 activity by bupropion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Interactions between herbal and conventional medicines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Update: clinically significant cytochrome P-450 drug interactions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

The pharmacogenetics of codeine hypoalgesia.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Pharmacogenetics: the slow, the rapid, and the ultrarapid

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Polymorphic hydroxylation of Debrisoquine in man.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population

8 July 2018

1 reference

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

CYP2D6 phenotype prediction from genotype: which system is the best?

21 January 2018

1 reference

The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity

21 January 2018

1 reference

Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles

21 January 2018

1 reference

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers

21 January 2018

1 reference

Absence of 'over-the-counter' medicinal products in on-line prescription records: a risk factor of overlooking interactions in the elderly

21 January 2018

1 reference

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe

21 January 2018

1 reference

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.

21 January 2018

1 reference

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers

21 January 2018

1 reference

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease

21 January 2018

1 reference

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

21 January 2018

1 reference

Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients

21 January 2018

1 reference

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

21 January 2018

1 reference

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

21 January 2018

1 reference

The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients

21 January 2018

1 reference

The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers.

21 January 2018

1 reference

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

21 January 2018

1 reference

Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response

21 January 2018

1 reference

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

21 January 2018

1 reference

Incidence and predictors of severe bleeding during warfarin treatment.

21 January 2018

1 reference

Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone.

21 January 2018

1 reference

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study

21 January 2018

1 reference

Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial

21 January 2018

1 reference

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

21 January 2018

1 reference

Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation

21 January 2018

1 reference

Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.

21 January 2018

1 reference

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

21 January 2018

1 reference

CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients.

21 January 2018

1 reference

Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.

21 January 2018

1 reference

The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers

21 January 2018

1 reference

[13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.

21 January 2018

1 reference

Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase

21 January 2018

1 reference

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

21 January 2018

1 reference

A randomized trial of genotype-guided dosing of warfarin.

21 January 2018

1 reference

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

21 January 2018

1 reference

A CYP2D6 Phenotype-Genotype Mismatch in Japanese Psychiatric Patients

21 January 2018

1 reference

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion

21 January 2018

1 reference

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.

21 January 2018

1 reference

Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.

21 January 2018

1 reference

Dynamics and persistence of CYP2D6 inhibition by paroxetine.

21 January 2018

1 reference

Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309629

Interaction of serotonin re-uptake inhibitors with perhexiline

25 October 2018

1 reference

12 December 2020

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned

1 reference

12 December 2020

Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol

1 reference

12 December 2020

In support of the European Union biosimilar framework

1 reference

12 December 2020

Changes in debrisoquine hydroxylation capacity following liver surgery

1 reference

12 December 2020

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

12 December 2020

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

12 December 2020

Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice

1 reference

12 December 2020

In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma

1 reference

12 December 2020

Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study

1 reference

12 December 2020

DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers

1 reference

12 December 2020

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment

1 reference

12 December 2020

The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study

1 reference

12 December 2020

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

12 December 2020

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4

1 reference

12 December 2020

Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6

1 reference

12 December 2020

Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibitors

1 reference

12 December 2020

The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline

1 reference

12 December 2020

Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects

1 reference

12 December 2020

Frequency and outcomes of concomitant use of proton pump inhibitors and clopidogrel after hospital discharge

1 reference

12 December 2020

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

1 reference

12 December 2020

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

12 December 2020

Identifiers

DOI

10.1111/BCP.12441

1 reference

5 August 2017

1 reference

5 August 2017

1 reference